Kenya’s national medicines regulator, Pharmacy and Poisons Board (PPB), has raised a public concern over falsified Ozempic Pens advising members of the public to be on high alert over buying or selling them.
PPB said it received interpol alert over the Ozempic Pens (Semaglutide) where Apidra Solostar pens (glulisine) used to treat both type 1 and type 2 diabetes has been falsely re-labelled as Ozempic (Semaglutide) Pens.
“Consequently, the Board would like to inform the public that Ozempic Pens are currently not registered or authorized by the PPB to circulate in the Kenyan market,” the board said.
The board has informed the public to be highly cautious when purchasing any product being marketed as Ozempic Pens because it is selling illegally in the market and the board cannot ascertain its safety, quality and effectiveness.
“Efforts in regard to safeguarding public safety has already been initiated by the Board,” PPB said.
PPB said rapid responses have been heightened through surveillance to verify whether the falsified Ozempic (Semaglutide) Pens is presently circulating in the Kenyan market.
“We encourage the public and healthcare professionals to immediately share any information regarding Ozempic pens with the Pharmacy and Poisons Board,” the board added.
contact information.
